Mobile

An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUP...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-005595-33

An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients with Prostate Cancer Requiring Androgen Ablation Therapy

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Primary objective: •To demonstrate non-inferiority with respect to the proportion of patients achieving and maintaining testosterone suppression to castrate levels using a degarelix dosing regimen compared to LUPRON DEPOT® during 12 months treatment

Critère d'inclusion

  • Prostate cancer

Liens